
Azenta and Form Bio Partner to Enhance AAV Gene Therapy
Azenta Life Sciences and Form Bio have announced a strategic partnership to enhance adeno-associated virus (AAV) gene therapy development. Announced in a press release, the collaboration aims to integrate GENEWIZ's next-generation sequencing services with Form Bio's AI-powered analysis pipelines.
The partnership focuses on providing gene therapy developers with data-driven insights into AAV capsid contents, improving safety, efficacy, and manufacturability. GENEWIZ will offer synthesis and packaging of transgene expression cassettes, along with high-quality, long-read sequencing services. Form Bio will utilize its Long-read AAV Analysis (LAAVA) software for comprehensive AAV Genome Integrity Characterization, offering actionable insights through detailed reporting.
This collaboration is set to officially launch at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in May 2025, where both companies will present their work on integrating sequencing and analysis workflows to accelerate the development of innovative therapies.
We hope you enjoyed this article.
Consider subscribing to one of several newsletters we publish like Life AI Weekly.
Also, consider following us on social media:
More from: Healthcare & Life Sciences
Ellipsis Health Unveils AI Care Manager Sage with $45M Funding
Deep Apple and Novo Nordisk Partner on Cardiometabolic Drug Discovery
Outcomes4Me Acquires Mika Health App to Enhance AI-Driven Cancer Care
AllSci Secures Grant to Enhance AI Platform for Pharma and Biotech
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read more